1Wei L, Debets B, Hegmans JJ, et al. IL - 1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-ganuna up-regulates the expression of keratin 17 and keratinocyte transg]utaminase via endogenous IL - 1 production. J Pathol, 1999, 187(3) :358 -364.
2el Barnawi NY, Giasuddin AS, Ziu MM, et al. Serum cytokine levels in psoriasis vulgaris. Br J Biomed Sci, 2001,58(1) :40 -44.
3Schon M, Behmenburg C, Denser D, et al. Pathogenic function of IL -1 beta in psoriasiform skin lesions of flaky skin (fsn/fsn) mice.Clin Exp Immunol, 2001, 123(3) .505 -510.
4Nishibu A, Han GW, Iwatsuki K, et al. Overexpreasion of monocytederived cytokines in active psoriasis: a relation to coexistent arthropathy. J Dermatol Sci,1999, 21 ( 1 ) :63 -70.
5Duan H, Koga T, Kohda F, et al. Interleukin-8- positive neutrophils in psoriasis. J Dermatol Sci, 2001,26(2) :119 -124.
6Szepietowski J, Walker C, Hunter JA, et al. Elevated leukaemia inhibitory factor (LIF) expression in lesional psoriatic skin: correlation with interleukin (IL) -8 expression. J Dermatol, 2001,28(3) :115- 122.
7Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol, 1999,135(2) :187 - 192.
8Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol, 2001,116(5) :721 -727.
9Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleuldn - 10 is associated with suppression of cutaneous type 1 inflammarion, downregulation of the epidermal interleukin - 8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Demmtol,2001, 116(2) :319 -329.
10Trepicchio WL, Ozawa M, Waiters IB, et al. Interleukin - 11 therapy selectivdy downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest, 1999, 104(11) :1527 -1537.
